key: cord-0939764-6q9hn5ro
authors: Simon, Arne; Schildgen, Oliver
title: Antimicrobial Therapy in Childhood Asthma and Wheezing
date: 2012-08-23
journal: Treat Respir Med
DOI: 10.2165/00151829-200605040-00004
sha: 0e0e7d26c7a45e86d0d6e1ff54334b48c334acae
doc_id: 939764
cord_uid: 6q9hn5ro

There is an increasing number of viral and bacterial pathogens suspected of contributing to asthma pathogenesis in childhood, making it more difficult for the practitioner to make specific therapy decisions. This review discusses the role of viruses, e.g. respiratory syncytial virus, human metapneumovirus, influenza viruses and rhinoviruses, as well as the role of the atypical bacteria Chlamydophila pneumoniae and Mycoplasma pneumoniae, as contributors to childhood asthma. Diagnosis, prevention, and therapy are discussed, including a summary of drugs, i.e. macrolide antibacterials, antivirals, and vaccine regimens already available, or at least in clinical trials. For the practitioner dealing with patients every day, drug regimens are assigned to the individual pathogens and an algorithm for the management of atypical infections in patients with asthma or recurrent wheezing is presented.

Besides hereditary and atopic predispositions, viral and atypi-1. Asthma cal bacterial infection of the respiratory tract may contribute to the Asthma has traditionally been defined on clinical grounds as a prevalence of asthmatic symptoms, either as a simple trigger for respiratory disease characterized by recurrent and reversible airacute exacerbations or as a significant contributor to the pathogenway obstruction with wheezing, cough, and dyspnea. In recent esis of airway inflammation and hyperresponsiveness. This article years, our understanding of asthma has expanded, and the special focuses on these factors in childhood asthma and wheezing, and impact of airway inflammation and, in severe cases, of airway comments on diagnostic issues and available treatment options.

remodeling on pathogenesis has led to a new definition which describes asthma as a chronic inflammatory process in which a as they may represent transient early wheezers. Although transient number of cells and cellular events are involved [1, 2] (reviewed by early wheezers were found to have normal-to-subnormal lung Yang [3] ). function at age 7 years, children with asthmatic symptoms already show significant impairment of expiratory flow volumes. [15] Any Repeated measurements of FEV1 (a general index of airway uncertainty, however, in the diagnosis of asthma in younger chilresistance) and PEF (which measures large airway resistance, dren must not result in undertreatment with anti-inflammatory which accounts for 80% of total resistance) have gained a global (controller) drugs, in addition to short-acting β2-adrenoceptor consensus to guide therapeutic interventions in patients >5 years agonists (reliever drugs). [3, 16] of age. Bronchial hyperreactivity is defined as a 20% decrease in FEV1 at ≤8 mg/mL methacholine challenge or >15% increase in 2.1 Differential Diagnosis FEV1 after the administration of albuterol (salbutamol) in patients with baseline airflow obstruction (FEV1 <70%) in whom a Particularly in infants and young children, some important methacholine challenge cannot be performed.

differential diagnoses have to be excluded before recurrent wheez-Patients with asthma also exhibit elevated levels of fractionated ing is attributed to bronchial hyperreactivity and asthma. In chilexhaled nitric oxide, which can be utilized as a marker of airway dren who did not receive the full set of vaccinations in their first inflammation. The measurement of fractionated exhaled nitric

year of life, whooping cough should always be excluded and oxide has been shown to enhance the diagnosis of asthma, detect droplet precautions should be implemented as long as the results of deterioration in the control of asthma, and monitor response to Bordetella pertussis diagnostics are pending. anti-inflammatory therapy, as levels decrease after inhaled corti-An aspirated foreign body may cause recurrent episodes of costeroid treatment, [4] especially in individuals with asthma and pulmonary infection. This makes it reasonable not only to confirm atopy. [5] The measurement of fractionated exhaled nitric oxide the clinical diagnosis of pneumonia with chest x-ray in hospitalmay become an important tool in clinical practice. [6] Furthermore, ized children, but also to control for the complete resolution of an increase in the sputum-associated immune cell (in particular pulmonary infiltrates after 4-6 weeks. Cystic fibrosis should also eosinophil) count should be taken into account during diagnosis, be excluded (sweat test) in any child with severe recurrent respirasince it is believed to reflect underlying airway inflammation. [7] [8] [9] tory tract infection. The eosinophil count can also be used to predict asthma control

The medical history of the patient may reveal prematurity and after the discontinuation of inhaled corticosteroids. [9] prolonged ventilator (supplemental oxygen) therapy with subsequent bronchopulmonary dysplasia. Gastroesophageal reflux dis-2. Recurrent Wheezing versus Asthma in ease (nocturnal attacks of wheezing and cough) may trigger recur-Early Childhood rent wheezing and respiratory infections due to microaspirations. Sinusitis as a cause of posterior drainage-associated chronic cough The risk of subsequent asthma in an infant with a first episode should be considered in school age children with asthma sympof wheezing is difficult to predict, as nearly 90% of those events toms. [17] Chronic persistent infection of the airways with atypical are triggered by viral infections, [10, 11] in particular respiratory bacteria such as Mycoplasma spp. or Chlamydophila spp. may syncytial virus (RSV), human metapneumovirus (HMPV), paraincause recurrent wheezing episodes; [18] [19] [20] beyond simple acute exfluenza virus (PIV), influenza virus (IV), rhinovirus, and adeacerbation, some recent lines of evidence suggest that infection novirus (ADV). HMPV and RSV in particular, but also rhiwith these atypical bacteria may play an additional role in the noviruses, [12] may contribute to acute exacerbations of asthma, and pathogenesis of asthma. [21] infection may represent the initial event in a history of asthma.

However, considering the plethora of viral agents the infant's 3. Endogenous and Exogenous Risk Factors immature immune system is confronted with after the shield of maternally derived antibodies has waned, recurrent wheezing may As a result of continuous research, the number of potential risk just be the consequence of recurrent infections or (in the cases of factors (e.g. tobacco smoke, house dust mite, mould, pet or cock-RSV and HMPV) even reinfections. In contrast to younger chil-roach allergens, and genetic background of atopy) for the developdren, the majority of children aged ≥3 years who are hospitalized ment of asthma is increasing (reviewed by Arruda et al.) . [22] for acute wheezing show characteristics of atopy in their medical Breastfeeding or, alternatively, the use of a documented hyhistory. [3, 10, 11, 13, 14] poallergenic formula for at least 4-6 months seems to be protec-It is important, therefore, to emphasize that recurrent wheezing tive. [23] This effect may be explained by the observation that rarely results in the final diagnosis of asthma in children ≤3 years, maternal intake of the probiotic Lactobacillus rhamnosus GG during late pregnancy followed by administration of L. rhamnosus ed). [31] [32] [33] This misuse of antibacterials may have biased studies GG to the infant for the first 6 months of life significantly that evaluated antibacterial treatment in early infancy as a risk decreased the proportion of children with atopic eczema in the factor for subsequent asthma. [29] However, it should be noted that verum group. [24] Thus, gut microflora might be a hitherto unexin contrast to this misuse, the sophisticated use of antibacterials, in plored source of natural immunomodulators and probiotics for particular macrolides, may downregulate prolonged inflammation, prevention of atopic disease. [24, 25] However, any protective effect increase mucus clearance, prevent biofilm formation, and also of frequent early exposure to (potential) pathogens and infections decrease the bacterial virulence (reviewed by Shinkai and on the prevalence of asthma has been questioned in further stud-Rubin). [34] ies. [26, 27] Thereby, only one prospective trial [28] fosters the hypothesis that antibacterial treatment in infancy is related to a higher risk of asthma later in life. [29, 30] 4

Nevertheless, too many wheezing episodes in infants triggered [55] reported on the same patients and compared children with For a long time it was believed that respiratory viruses were RSV with those with rhinovirus infection. Oxygen saturation solely responsible for the 'common cold' and for serious airway values were lower in children with RSV infection. There were no disease only in high risk patients such as prematurely born infants, significant differences in respiratory rates or scores combining the elderly, and the immunocompromised. Subsequently, it was wheezing and retractions. The children with rhinovirus infection widely recognized that viral respiratory infections may cause were older (median 13 vs 5 months) and presented more often with severe lower respiratory tract disease in immunocompetent indiatopic dermatitis (OR, 16.7; 95% CI 2.22, 100) and blood eosividuals. [35] In addition, viral respiratory tract infections are closely nophilia (OR, 2.22; 95% CI 1.04, 50). The groups did not differ linked to wheezing in infancy and to hospitalization for acute from each other with regard to total serum IgE. The risk of wheezing before 3 years of age. [10, 11, 36, 37] By comparison, a large subsequent asthma was increased about 5-fold after RSV-induced majority of wheezing children aged 3-18 years display additional wheezing, and ≥10-fold after rhinovirus-induced wheezing in the atopic characteristics that may be critical as a risk factor for most recent patient collective. [56] hospitalization and an adverse response to viral infections, espe-Lemanske et al. investigated the role of RSV infection in a cially to rhinovirus, the most prevalent causative agent in this age prospectively followed (from birth to 3 years of age) cohort of 285 group. [37] In asthmatic children, bronchial hyperresponsiveness children at genetically high risk for developing allergic respiratory after a single 'natural cold' has been found to last 5-11 weeks. [38] diseases. [12] When viral etiology was considered, first-year wheez-Beyond RSV and rhinovirus, the newly detected viruses HMPV, ing illnesses caused by rhinovirus infection were the strongest human coronavirus NL63 (hCoV-NL63), and human bocavirus predictor of subsequent third-year wheezing (OR, 6.6; p < 0.0001). may substantially contribute to acute asthma exacerbations. [39] [40] [41] [42] [43] [44] Moreover, 63% of the infants who wheezed during rhinovirus The more severe clinical course of viral bronchiolitis in infants has seasons continued to wheeze in the third year of life, compared been linked to inherited abnormalities of pulmonary function [45] with only 20% of all other infants (OR, 6.6; p < 0.0001). Also, and to certain risk factors like chronic lung disease of prematurity, similar mechanisms have been speculated to be active in severe hemodynamically relevant congenital heart disease, neurologic bronchiolitis caused by rhinovirus, [57] but the evidence that rhiimpairment, and immunodeficiency. [46] novirus-like RSV contributes to the pathogenesis of asthma in In addition to acute aggravation of any pre-existing airway childhood is not as consistent and requires investigation in further disease, RSV infection of the lower respiratory tract, in infants, prospective trials. severe enough to cause hospitalization has been linked to subse-Juntti et al. [58] showed that children hospitalized for RSV infecquent bronchial hyperreactivity, recurrent wheezing and asthma in tion in infancy still differed in interferon (IFN)-γ and soluble school age children up to the age of 13 years. [13, 14, 47, 48] Interestingintercellular adhesion molecule-1 (sICAM-1) [CD54] production ly, children with recurrent wheezing after their first RSV bronchi-6-10 years after the infection. Data from 51 children admitted to olitis displayed elevated IgE antibodies against common respiratohospital for RSV infection during the first year of life suggested ry and food allergens as well. [13, 47] Thus, it has been speculated that that the pathogenesis of asthma and wheezing after an early RSV lower respiratory tract infection with RSV triggers a general shift infection may be different from that in children without an early of the immune system in favor of atopy (dominance of T helper RSV infection. The latent or chronic inflammatory state of the type 2 response, upregulating IgE production with higher levels of airways in asthmatic or atopic individuals may alleviate the infecinterleukin (IL)-4, IL5, IL10 and IL8 in bronchial secretion with rhinovirus due to an increased expression of sICAM-1, tions). [45, [49] [50] [51] [52] Similar changes in the immune system have been hitherto known as the key receptor only for rhinoviruses and implicated for the devastating consequences of the first RSV necessary for their adhesion to the respiratory epithelium. [59] immunization campaign with a formalin-inactivated RSV vaccine that resulted in severe and even lethal illness in the immunized

children. [53] The diagnostics of viral respiratory tract infections relies on In a series of recent publications on a retrospective study from different methods and, in general, depends on the skills and the Kuopio University Hospital, Finland, rhinoviruses were deexperiences of a virological laboratory. tected in 27 (33%) of 81 respiratory samples from children who had been hospitalized for wheezing in infancy. [54] As single viral Fortunately, some of the viruses causing respiratory infections findings, rhinoviruses were associated with the development of can be cultivated in permissive cell cultures, provided that the asthma 7 years later (p = 0.047; odds ratio [OR], 4.14; 95% CI necessary equipment and technology are available. However, as the culture method is sometimes time-consuming and the viruses respiratory infections in infants, the contribution of atypical bactemay be extremely difficult to recover, e.g. in the case of hCoV-rial pathogens to the inception of asthmatic symptoms in this age NL63 and HMPV, [42] [43] [44] 60] other more rapid diagnostic methods group might be underestimated. [52, 63] A recently published review like reverse transcriptase polymerase chain reaction (RT-PCR) or by Johnston and Martin [64] on this issue included nine studies in antigen detection assays are preferred in clinical practice. Antigen pediatric patients (table II) , as well as other studies in adults. The detection by the enzyme-linked immunosorbent assay (ELISA) main results of these trials in children are included in table II. method is available for RSV, IV, PIV and ADV and provides a Johnston and Martin came to the conclusion that in 15 out of 19 positive or negative result between 15 minutes and 3-6 hours. studies, a relationship was evident between asthma and infections However, until such assays are developed for routine use for with M. pneumoniae and C. pneumoniae. [64] newly detected pathogens like HMPV or hCoV NL-63, [43] the C. pneumoniae is a respiratory pathogen distributed worldwide, method of choice is to detect the viral nucleic acid. Thus, PCR or which causes conjunctivitis, pharyngitis, bronchitis and pneumo-RT-PCR plays a crucial role in the detection of newly detected nia (with pleural effusion in some cases). A subacute onset and a viral respiratory pathogens. For most of these agents, however, it prolonged period of convalescence with ongoing malaise and is still unknown how long the PCR remains positive in respiratory cough are characteristic. While symptoms of acute sinusitis often specimens after the cessation of the clinical illness.

accompany acute infection with C. pneumoniae, its causative role Besides the high sensitivity of the RT-PCR/PCR, this method is in chronic sinusitis in school age children has been questioned. [74] advantageous in detecting additional infection by another virus, Nearly 10% of community-acquired pneumonias in children ≥5 commonly described as co-infection. However, as the viral RNA years of age are caused by C. pneumoniae; the highest incidence is may take 5-6 weeks to disappear from nasal mucus, e.g. after the found in school-age children and adolescents, and about 50% of onset of symptomatic respiratory infection by rhinoviruses, [61] it adults display serum IgG antibodies against the pathogen. It is an may not be clear which of the viruses detected is responsible for obligate intracellular parasitic bacterium which utilizes the energy the clinical symptoms. Therefore, the duration of detection should metabolism of the human host cells for its replication. C. be investigated, to avoid false positive PCR results, weeks or pneumoniae is transmitted by direct contact, droplets and (to a possibly months after the first infection. much lesser extent) by aerosol nuclei or fomites in conditions of high relative humidity. The incubation period is approximately 21 days, [52, 75] and the attack rates are relatively low, even in family 4.2 Bacterial Infections contacts. Infection with C. pneumoniae is usually followed by a specific immune response of IgM, IgG and IgA antibodies against Any chronic respiratory tract infection may contribute to the certain bacterial antigens. This humoral immune response is not aggravation of symptoms in patients with asthma, as the immunoobligate; in particular, infants and young children may fail to logical response to the infection may foster the development of mount sufficient antibodies in spite of culture-confirmed infecbronchial hyperreactivity, the inception of new atopic symptoms tion. [75] [76] [77] [78] [79] [80] Thus, it is not clear whether the immune response can be against common respiratory allergens, and the chronic inflamused to differentiate between colonization and infection in young matory and remodeling process of the airways, [50, 51] although the children. contribution to the latter remains highly speculative. On the other Hahn et al. first observed in 1991 [81] that 9 of 19 wheezing hand, chronic pulmonary inflammation and its deleterious effects adults displayed serologic signs of an infection with C. on mucociliary clearance, drainage of mucus and cell debris and pneumoniae. These findings were extended 5 years later when the reduced airway patency enable the development of viral and same group suggested that the detection of IgA antibodies against bacterial superinfections.

C. pneumoniae corresponded with a higher probability of recent There is a consensus that typical bacterial respiratory pathogens asthma symptoms. [82] Furthermore, in school-age children with such as Streptococcus pneumoniae or Haemophilus influenzae wheezing, Cunningham et al. [67] observed an unusually high numhave not been associated with the exacerbation or the inception of ber of individuals with low-grade C. pneumoniae infection. childhood asthma, and that the routine administration of β-lactams to patients with asthma exacerbations provides no significant

In contrast to viral respiratory infections, C. pneumoniae conbenefit. [52, 62] tributes only rarely to acute asthma exacerbations, [69] but an asso-The potential contribution of atypical bacteria, in particular ciation between chronic infection with C. pneumoniae and the Mycoplasma pneumoniae and Chlamydophila pneumoniae, to the subsequent onset of asthma has been suggested by some authors. onset and persistence of childhood asthma is still a matter of Nagy et al. [70] found a significantly higher risk of asthma in ongoing debate. [ Emre et al. [66] (1995) Culture-positive children with stable Culture IgE against C. pneumoniae was detected significantly more often asthma (n = 14); 11 culture-negative Serology, including IgG, IgM in culture-positive asthmatic children than in culture-negative asthmatic children; 11 culture-negative (MIF) and IgE (EIA) asthmatic children and in controls (86% vs 18% vs 22%; p < controls 0.001 and p < 0.006, respectively) The authors speculated that the production of specific IgE against C. pneumoniae may foster the development of asthma Cunningham et al. [67] Longitudinal study over 13 months in PCR (NPA); EIA for secretory 43 of 96 (45%) children with asthma displayed a positive C. Mills et al. [68] (2000) 198 subjects from a prospective birth Serology, including IgG and No statistically significant correlation between symptoms cohort study at age 11y (n = 66) and

IgA (MIF) suggestive of asthma in the previous 12 months and either IgG at age 21y (n = 96) or IgA antibody levels. Individuals with high IgG titers (≥128) even showed a protective effect against ever having asthma (OR 0.29; CI 0.10, 0.87) Conclusion: C. pneumoniae is not a major risk factor Esposito et al. [69] airway hyperresponsiveness in RSV infection [21] Nagy et al. [70] Although atypical infections were linked to prolonged asthmatic and C. pneumoniae symptoms, no correlation between infection and severity of chronic asthma or asthma exacerbations was found

Korppi et al. [72] (2004) 122 children aged 1-6y, treated for MIF for C. pneumoniae and C.

IgG antibodies to C. pneumoniae, though common in 1-to new asthma as inpatients or trachomatis antibodies; EIA for 6-year-old children as detected by EIA (31-36%), did not differ outpatients; 244 controls, matched by C. pneumoniae antibodies between newly diagnosed asthma patients and controls age, sex and municipality

The prevalence of IgA antibodies (EIA) was much lower (4-7%) but likewise not different between patients and controls

Biscardi et al. [18] nose-binding lectin alleles (confirmed by PCR), in particular in detection of rhinovirus, the most important viral pathogen in asthma exacerbations in school-aged children. [22, 37, 55, 63] those with chronic infection (confirmed by both positive IgG and IgA antibodies). Mills et al., [68] however, could not determine a significant correlation between C. pneumoniae serology and asth-

ma (table II) . Because of its retrospective nature (antibodies were A series of very detailed investigations of the clinical, laboratodetected in stored serum samples), no results from culture or PCR ry, and radiologic presentations of community-acquired pneumowere available to identify which patients harbored C. pneumoniae nia in children under the age of 5 years revealed that no combinain their airways. In addition, only 22.9% of all individuals reporttion of clinical signs, host acute phase response markers at any cuting asthma symptoms showed a bronchial hyperreactivity and the off value, or radiologic findings reliably differentiates between authors did not differentiate according to the two age groups (11 bacterial and viral or between atypical and typical pneumonia in and 21 years; table II). The authors emphasized in their discussion this age group. [72, [87] [88] [89] Thus, microbiologic diagnostic efforts are that seroconversion is not universally associated with clinical indispensable to identify the responsible respiratory pathogen. infection and questioned the principle of assessing the effect of a Initially, C. pneumoniae was designated as TWAR strain of C. respiratory infection on a chronic pulmonary disease simply by the psittaci, [90] but differences in DNA sequences, epidemiology, and measurement of antibody titers in serum.

also pathogenicity led to the actual classification of this pathogen. On the contrary, two groups found an inverse correlation be-Furthermore, there is a high prevalence of IgG antibodies against tween C. pneumoniae respiratory tract infection and the inception C. pneumoniae in the general population (>50% in adults). [90] of asthma or allergic rhinitis in children. [83, 84] Such data about the Thus, the laboratory diagnosis, in general, is based on serologic role of C. pneumoniae in the inception and development of asthma testing. in children are intriguing, but somewhat controversial; further well As a result of a consensus conference held at the Centers for designed studies are needed. One recently published study [73] Disease Control and Prevention, USA, Dowell and colleagues [91] (table II) not only detected C. pneumoniae in bronchoalveolar concluded that acute infection with C. pneumoniae is accompanied lavage (BAL) samples from asthmatic children with PCR, but also by the appearance of IgM antibodies that can be detected 2-3 confirmed the viability of the pathogen in culture, and correlated weeks after the onset of clinical symptoms. Thereafter, IgM anan elevated total level of IgE with lavage culture positivity for C.

tibodies are detectable up to 2-6 months and are replaced by low pneumoniae. The authors concluded that viable C. pneumoniae are titers of IgG antibodies that firstly appear 6-8 weeks after infecfrequently present in BAL specimens from symptomatic children tion. Dowell and colleagues concluded that the use of a single with asthma. [73] parameter will not lead to a complete diagnosis and that PCR, although not yet standardized, will be of increasing importance as M. pneumoniae is a common pathogen in upper and lower a future tool for diagnosis. Furthermore, they stated that 'there are airway infections including otitis media, pharyngitis, [85] tracheno wholly satisfactory serological methods for diagnosis of C. obronchitis and pneumonia in all age groups older than 12 pneumoniae infection.' [91] months. [86] M. pneumoniae is an extracellular mucosal pathogen attached to the respiratory epithelium via a specific part of its cell, The PCR method for pathogen detection is of increasing importhe organelle. The extent to which it invades and replicates intance for the second atypical bacterial pathogen related to asthma, tracellularly in vivo is not known. [21] The cellular and humoral M. pneumoniae. However, the major obstacle to the use of PCR as immune response to the infection is responsible for clinical illness the single method for the detection of M. pneumoniae or C. and airway injury. Acute infection is accompanied by lymphocyte pneumoniae is that it does not distinguish between viable and proliferation and the release of tumor necrosis factor (TNF)-α, nonviable bacteria, for example after antibacterial chemothera-IFNγ, and various interleukins (IL2, IL4, IL5, IL6, IL8, IL10, and py. [92] Thus, at least one other method is recommended for the IL18). [21] laboratory diagnosis of both infections.

However, the distinct role of M. pneumoniae in asthma patho-The most frequently used method to detect specific antibodies genesis still has to be resolved. [16, 50] Biscardi and colleagues [18] in the majority of studies that investigated an association between have reported the highest prevalence of M. pneumoniae infection; asthma and C. pneumoniae infection is the microimmu-50% of children with a first asthma attack, and 20% of children nofluorescence test. [64, 91] Alternative serological assays have been with previously diagnosed asthma and acute severe exacerbation.

described, but the lack of commercial availability and limited Although the authors searched for viruses, they did not use PCR specificity (cross-reactive antibodies) have impeded their broader methods and no immunofluorescence assay was available for the use in practice. [91, 92] The laboratory diagnosis of M. pneumoniae is more complex authors developed the Pneumoplex ® 1 assays that combine multiand even more difficult. Although M. pneumoniae can be cultivat-plex PCR and hybridization assays while being highly specific and ed on solid media, its growth is extremely slow (≥6 days), and the highly sensitive. culturing methods are extremely insensitive. Thus, it is difficult to 5. Prevention and Treatment of Viral Infections get a rapid diagnostic result with this method. However, M. pneumoniae can be isolated from swabs, retronasal aspirates, Almost 50 years after the first description of RSV, physicians sputum, or BAL. In all cases where the subsequent culturing of the attending children with viral respiratory tract disease and asthma pathogen is required or desired, the specimen should be solved are still awaiting the development of effective and economically (i.e. material should be mixed with medium) in adequate transporinexpensive medications for the prevention and treatment of retation media. For rapid detection, the material can be investigated spiratory viral infections in infants. [45] For the majority of respirawith enzyme immunoassays, oligonucleotide hybridization methtory viruses there is no specific therapy available to impede ods, or PCR assays.

infection or to inhibit viral replication in the infected host. In most While culturing on solid-phase media, middle-sized granulated cases, treatment is symptomatic with no specific intervention colonies without the typical 'fried egg' appearance are formed. For fighting the pathogen. In contrast to bronchiolitis in hospitalized orientation, M. pneumoniae can be identified via glucose cleavage infants and children without a history of asthma or recurrent reactions, hemadsorption, and hemolysis, and finally the identifiwheezing, [31, 94] the early administration of systemic corticostecation procedure can be finished by a growth inhibition test and/or roids represents the primary means of treatment in severe asthma epifluorescence. Because of the insensitive culturing method and exacerbations, [3, 16] The neuraminidase inhibitors oseltamivir and zanamivir are This assay has the general limitations that it is: (i) impossible to active against influenza viruses and are available for the treatment differentiate antibody subclasses; (ii) lacks specificity; and thus, of microbiologically confirmed influenza. [95] These substances (iii) cannot differentiate between acute, chronic, or previous infecinhibit the enzymatic activity of neuraminidase and are thought to tions. [64] Meanwhile, the commonly used serologic test that reprevent the release of newly budded progeny virions from the cell placed complement fixation is the ELISA method, which has the surface. The neuraminidase inhibitors have to be used very early major advantage that there some assays commercially available (within the first 72 hours) during the course of the disease, or even and these tests specifically differentiate between different stages as a chemoprophylaxis. Thus, a rapid laboratory diagnostic test of the infection. [64] that detects the viral RNA or the viral antigen is mandatory to guide decisions on treatment. All in all, the diagnosis of atypical respiratory tract infection is Another possibility to prevent influenza-triggered asthma is to still laborious, sophisticated, expensive, and time consuming. prevent the infection by vaccination. Although this possibility is There is an urgent need for sensitive, specific, standardized, and highly desirable, the major disadvantage is that vaccination targets economically inexpensive diagnostic tests that can be used at the actual influenza strains. In epidemic seasons, when new strains bedside or at least yield results within 2-6 hours. [18] Only if the emerge (as most recently observed for the avian influenza virus pathogen can be easily identified and its detection can be definitely H5N1), a new specific vaccine must be developed and, in general, attributed to infection (vs colonization) will it be possible to is available only in the middle of the ongoing epidemic or for the confirm its role in the inception of the chronic inflammatory next epidemic season. However, we strongly recommend vaccinaprocess; prospective randomized studies on the best therapeutic tion of any high-risk group, especially those with an increased risk intervention can then be performed. [69] Modern multiplex PCR of asthma. In the near future, newer vaccine formulations and live, approaches detect an extended spectrum of pathogens in parallel, attenuated influenza vaccine strains [96] [97] [98] [99] may complement current thereby reducing costs for material and personnel. Although this vaccination strategies. approach is intriguing, the 'reality check' of some published methods often yields much lower detection rates than expected.

A specific passive immunoprophylaxis and also a nonspecific This problem will probably be overcome by the recent 'upgrade' antiviral therapy are available to prevent or treat infections with of these multiplex assays as described by Khanna et al. [93] These human RSV. The first option is immunoprophylaxis with palivizumab, a humanized monoclonal antibody binding to the may be another future option for the treatment of rhinovirus highly conserved F protein of both RSV-A and RSV-B subinfections as it inhibits the attachment of virus to host cell receptypes. [32] The efficacy of palivizumab (mainly a significant reductors and the uncoating of viral nucleic acid. [109] Pleconaril can be tion of the percentage of children who have to be rehospitalized applied orally and is distributed to the upper and lower airways with RSV infection in the first 24 months of life) was tested in two after enteral absorption. Infection with rhinoviruses, however, has well-designed, prospectively randomized, double-blind mulnot been a major inclusion criterion in clinical studies of ticenter studies. [100] However, the prophylactic use of this antibody pleconaril. [110] is limited due to its high cost; thus, its application is recommended ICAM-1 is an important cellular receptor for the attachment of only for high-risk premature infants, for infants with hemodynamrhinoviruses. There have been experimental approaches to inhibit ically relevant congenital heart disease, [46] and (not at the same the virus-receptor interaction by monoclonal antibodies or antagolevel of evidence) in RSV-infected patients after allogenic blood nistic molecules. One antibody-like compound CFY 196 is a stem cell transplantation. [101, 102] recombinant antibody fusion protein and may be a promising • Antiviral therapy for RSV infections is possible and sometimes candidate for further investigations and clinical trials. Another successful with ribavirin, administered by the inhalation of compound, sICAM-1 (tremacamra), consists of an ICAM-1 deriaerosols from a small-particle aerosol generator. This therapy vate in which the transmembrane and intracellular domains have may be an option in the case of life-threatening RSV infections been truncated. in mechanically ventilated premature infants or in severely Specific therapies or vaccinations are lacking for human immunocompromised children. In the latter group, ribavirin has metapneumovirus and respiratory coronaviruses. Furthermore, been suggested as a treatment option in patients with severe data on experimental usage of antivirals in vitro that should inhibit influenza or parainfluenza virus infection. [102] Even in those the replication of these viruses are ambivalent and not very promhigh-risk populations, its routine use is controversial due to a ising, and even the development of specific vaccines has not yet lack of evidence of a significant benefit in randomized controlled studies, as well as cost issues, and potential toxicity (and been as successful as expected. teratogenicity) in both patients and exposed caregivers. [103] One For human metapneumovirus, as for the other 'untreatable' study of ribavirin use in infants with severe bronchiolitis, viral pathogens, prospective controlled studies are needed to conobserved a long-term benefit on subsequent airway hyperfirm or refute the efficacy of any therapeutic intervention in infants reagibility. [104] Even if this could be confirmed in further conand children with recurrent wheezing, asthma, bronchiolitis, or trolled trials, no valid clinical or laboratory parameter indicates pneumonia. It should be proven in prospectively randomized which subgroup of patients will experience such a positive double-blind studies with sufficient power that a certain therapeuoutcome.

tic intervention has a positive impact on illness severity (breath • As reviewed by Weinberger, [52] a number of compounds are rate and oxygen saturation), length of inpatient care, and the known to display only marginal cytotoxic effects while being necessity to admit the patient to the intensive care unit or to start highly active against RSV in inoculated tissue culture. Three mechanical ventilation. It is also important to identify evidencecompounds are already being tested in phase I or phase II trials:

based treatment methods to avoid the unjustified consumption of pleconaril, RSV 604 (A 60444), and RF I641. [52, 105] However, financial resources. In this context, systemic treatment with cortineither ribavirin nor any of the new therapeutic agents active costeroids [31, 111, 112] or inhalation treatment with beta mimetics or against RSV have been assessed or licensed for use in children adrenaline (epinephrine) [31, 111, 112] should be investigated critically. with recurrent wheezing or asthma. [52] For example, in epidemiologic studies published up till 2005, The respiratory viruses most frequently detected in school-age 26-44% of all HMPV-infected hospitalized pediatric patients rechildren with asthma are the rhinoviruses. While no specific ceived systemic corticosteroids, and half of them were treated with treatment against rhinoviruses is available yet, an increasing numbronchodilators. Due to the increasing number of clinically releber of promising drug candidates are under development or even in vant viral respiratory pathogens and also the increasing number of the early phase of clinical trials. One of these drugs that has newly developed antiviral drugs, the absolute prerequisite for a successfully passed a phase II clinical trial is rupintrivir, [106] a specific treatment remains a rapid and specific diagnostic apselective irreversible inhibitor of the rhinoviral 3C-protease which proach. is administered intranasally. It is a peptidomimetic compound with Specific therapy options for viral infections are summarized in poor aqueous solubility and low oral bioavailability in animals, [107] but it was well tolerated in healthy adult volunteers. [108] Pleconaril table I.

Taken together, results from Italy [69, 113] and France [18] support the use of antimicrobials in patients with asthma and microbiologically confirmed M. pneumoniae or C. pneumoniae infection. Schmidt et al. [114] recently demonstrated that in children with therapy-refractory bronchitis or pneumonia, bronchial C. pneumoniae co-infection was associated with more severe disease. In their study, and others, [87, 115] adequate antibacterial therapy for C. pneumoniae infection was shown to improve pulmonary function. Figure 1 presents an algorithm for the management of atypical pulmonary infections in patients with asthma or recurrent wheezing.

In this context, the principle aims of treatment are:

• The infection should be eradicated, not only suppressed. [79, 80, 116] However, this seems to be not so easy to achieve in C. pneumoniae infections. Therefore, some authors recommend an empirical second cycle of treatment if symptoms persist or recur. [90] • Relief of acute symptoms in patients with acute infection should be prompt (those infections are self-limiting diseases in immunocompetent persons).

• The number and the severity of recurrent wheezing exacerbations during follow up should be reduced. [18, 69] • The inflammatory stimulus of chronic pulmonary infection with atypical pathogens on the underlying pulmonary disease should be stopped and the adverse effects of the cellular and humoral immune response on bronchial hyperreactivity should be contained. [19, 21, 113] The microbiologic targets are obligate intracellular organisms (C. pneumoniae) or bacteria without a common Gram-positive/ Gram-negative cell wall, rendering both pathogens a priori resistant to all β-lactams, glycopeptides, and carbapenems. In addition, M. pneumoniae is not susceptible to sulfonamides, rifampicin, or linezolid.

First-line agents for the treatment of infections due to M. pneumoniae or C. pneumoniae in children are the macrolides (erythromycin, clarithromycin, or roxithromycin) and the azalide azithromycin. Erythromycin and clarithromycin are available as also individual local legal restrictions, may limit the use of an intravenous preparations if the condition of the child does not antimicrobial agent. allow oral medication. In children ≥8 years of age, intravenous doxycycline may be used as a feasible alternative, although there Third-line agents for the treatment of atypical pneumonia in are no comparative studies on the use of doxycycline in children severely immunocompromised children and adolescents are the and adolescents besides its use in the treatment of tick-borne fluoroquinolones (i.e. levofloxacin and moxifloxacin) or the infections, melioidosis, or brucellosis. [117] [118] [119] [120] However, at least in ketolide telithromycin. Due to potential toxicities, [121] licensing the US, azithromycin is available for intravenous use, but not issues and general considerations not to increase selective pressure clarithromycin, demonstrating that not only scientific reasons, but on resistant pathogens, [122] the use of these agents is not standard in children with recurrent wheezing or asthma, and are thus beyond may be combined without subsequent problems, e.g. for example the scope of this review.

with cyclosporin after stem cell or organ transplantation. [134] From a microbiologic perspective, it seems reasonable to use 6.2 Duration of Treatment clarithromycin (15 mg/kg/day in two doses for at least 14 days) as a first-line agent as it displays very promising in vitro sensitivity

No controlled trials are available on the optimal duration of results, with minimum inhibitory concentrations ≤0.001-0.125 treatment in childhood atypical bacterial tracheobronchitis or μg/mL (as do erythromycin and azithromycin). A prospective pneumonia. Considering the observation of persistent colonization randomized study of 124 children treated with clarithromycin after conventional treatment regimens, in particular in C. (tested against erythromycin ethylsuccinate 40 mg/kg/day in two pneumoniae infections, [79, 80, 116] it seems reasonable to use a proor three divided doses in 110 patients) confirmed clinical and longed treatment schedule in children with asthma and confirmed radiologic success in 98%, and an eradication of M. pneumoniae in atypical bacteria infection, as suggested by Esposito et al. [113] for 100% (n = 9). [123] C. pneumoniae was eradicated in 79% (culture). azithromycin (i.e. 10 mg/kg/day for 3 days per week in 3 consecu-The gastrointestinal tolerability of clarithromycin seems to be tive weeks). Alternatively, the use of clarithromycin for at least better than that of erythromycin and it can be administered twice 14-21 days may be considered. [90] Further well designed, randomdaily.

ized and controlled trials are clearly needed to examine the effec-In contrast to azithromycin, the pharmacokinetic pattern of tiveness of different antibiotics against M. pneumoniae or C. clarithromycin does not result in prolonged subtherapeutic plasma pneumoniae and the optimal dose and duration of therapy in levels and an increased risk of subsequent colonization with various patient populations.

[135] macrolide-resistant pneumococci. [124] [125] [126] This clinically relevant observation has been refuted by others. [28] Arguments for the use 7. Conclusion of azithromycin are: it is highly active in vitro; [21] at least two Although the number of pathogens suspected to be associated randomized controlled trials in children confirmed its efficacy and with acute or chronic asthma pathogenesis in childhood is increassafety against atypical community-acquired pneumonia; [127, 128] ing, the number of options for specific therapies available now or children find the color and taste of the oral suspension of azithroin the near future is also increasing. Thus, before starting a therapy mycin agreeable; and the drug is well tolerated. [129] It is adminisit is strongly recommended that clinicians perform a rapid clinical tered in a single daily dose. In addition, a substantial line of and laboratory diagnosis accompanied by a detailed history. evidence suggests that azithromycin displays favorable immu-Thereafter, a specific and individual therapy regimen should be nomodulatory and anti-inflammatory effects in patients with considered in order to avoid the development of resistance and to chronic inflammatory pulmonary diseases like cystic fibrominimize drug-specific adverse effects or unnecessary drug intersis, [130, 131] and bronchiolitis obliterans after stem cell transplantaactions. In this manner, treatment may avoid acute and/or chronic tion. [132, 133] Interestingly, Esposito et al. [113] investigated the use of asthma in the affected patient. azithromycin in children >8 years of age and with a physician's diagnosis of recurrent respiratory infections. Their results in the

Hydrofluoroalkane formulations of inhaled corticosteroids for 32. Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune the treatment of asthma

healthy respiratory syncytial virus-infected young children admitted to the intensive care unit

Eosinophilic inflammation in asthma

Macrolides and airway inflammation in children

Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with 35. Papadopoulos NG. Do rhinoviruses cause pneumonia in children? Paediatr Respir mild asthma

Metapneumovirus and acute control after discontinuation of inhaled corticosteroids

Respiratory picornaviruses and respiratory

Viral infections in relation to age, syncytial virus as causative agents of acute expiratory wheezing in children. atopy, and season of admission among children hospitalized for wheezing

Duration of postviral airway

Human metapneumovirus infechyperresponsiveness in children with asthma: effect of atopy. J Allergy Clin tion in children hospitalized for wheezing

Cloning of a human parvovirus by

Rhinovirus illnesses during molecular screening of respiratory tract samples

New variant of the human

RSV bronchiolitis and risk of wheeze and metapneumovirus (HMPV) associated with an acute and severe exacerbation of allergic sensitisation in the first year of life

Wheezing in patients with human bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care metapneumovirus infection

Transient early wheeze is not associated with pneumovirus isolated from young children with respiratory tract disease. Nat impaired lung function in 7-yr-old children

Human metapneumovirus infecchildren with mild asthma: the effect on bronchial hyperresponsiveness. Chest tion in children hospitalized for wheezing

Effects of viral respiratory infections children

Cytokine secretion in children with acute Mycoplasma pneumoniae infection and wheeze

Selected populations at increased risk from respiratory syncytial 122-7 virus infection

Asthma and immunoglobulin E hospitalization: effect of mixed infection on clinical outcome

Respiratory syncytial virus in early life and pathogen

Risk factors for asthma and atopy

Mechanisms of respiratory virus-induced

Prevention of allergic disease in childhood: clinical and epidemiological 50. Montalbano MM, Lemanske Jr RF. Infections and asthma in children. Curr Opin aspects of primary and secondary allergy prevention

Clinical patterns and natural history of asthma

disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 52. Weinberger M. Respiratory infections and asthma: current treatment strategies

Effect of probiotics and breastfeeding 53. Polack FP, Karron RA. The future of respiratory syncytial virus vaccine developon the bifidobacterium and lactobacillus/enterococcus microbiota and humoral ment

Does previous infection protect against atopic wheezing in infancy: the first sign of childhood asthma? J Allergy Clin eczema and recurrent wheeze in infancy?

Rhinovirus-associated wheezing explanation for the increased prevalence of asthma?

Mode of delivery and risk of developing 56

Antibiotic use in the first year of

The link between bronchiolitis and asthma

Use of antibacterials in infancy: clinical implications for

Serum concentrations of interferon-gamma

Bronchiolitis: assessment and evidence-based manand intercellular adhesion molecule-1 eight years after an early respiratory agement

Aetiology of acute pharyngitis: the role of induced up-regulation of the rhinovirus receptor intercellular adhesion moleatypical bacteria

cule-1 (ICAM-1) in respiratory epithelial cells

Mycoplasma pneumoniae respiratory disease symposium: summa

Human metapneumovirus and chronic tion and significance

Mixed microbial aetiology of community-acquired pneumonia in chil

Persistence of rhinovirus and enterovirus dren

RNA after acute respiratory illness in children

Serum procalcitonin concentrations in 62. NAEPP. Use of antibiotics to treat asthma exacerbations

Viral respiratory infection and the link to asthma. Pediatr Infect Dis J 89. Korppi M. Non-specific host response markers in the differentiation between

Chlamydophila pneumoniae and Mycoplasma pneumoniae: a role in asthma pathogenesis?

Chlamydia pneumoniae (TWAR)

Standardizing Chlamydia pneumoniae infection and reactive airway disease in children

Detection of anti-Chlamydia

pneumoniae IgE in children with reactive airway disease

Chlamydia pneumoniae infections in asthma: clinical implica

The pneumoplex assays, a multiplex infection and asthma exacerbations in children

Chlamydia pneumoniae serological organisms, Mycoplasma pneumoniae, Chlamydia (Chlamydophila) status is not associated with asthma in children or young adults

Importance of acute Mycoplasma pneumoniae 94. Panitch HB. Viral respiratory infections in children with technology dependence and Chlamydia pneumoniae infections in children with wheezing

The development of asthma in children neuraminidase inhibitors: detection, incidence, and implications of drug resisinfected with Chlamydia pneumoniae is dependent on the modifying effect of tance

mannose-binding lectin

Effectiveness of live

Role of viruses and atypical intranasal influenza virus vaccine in healthy, working adults: a randomized bacteria in exacerbations of asthma in hospitalized children: a prospective study controlled trial

in the Nord-Pas de Calais region (France)

Chlamydia pneumoniae and newly induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus diagnosed asthma: a case-control study in 1 to 6-year-old children. Respirology vaccine

Prevention of otitis media in children with live attenuated

The bronchial lavage of pediatric influenza vaccine given intranasally

The role of Chlamydia pneumoniae cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) infection in children with chronic sinusitis. Arch Otolaryngol Head Neck Surg and B using surveillance cultures

Br hospitalization due to respiratory syncytial virus in young children with

Mycoplasma pneumoniae and Chlamydia

syncytial virus-specific monoclonal antibody palivizumab in recipients of hem

Use of antimicrobial agents for communityatopoietic stem cell transplants

Asthma in children: are chlamydia or mycoplasma in

Ribavirin in ventilated respiratory 79. Hammerschlag MR. Advances in the management of Chlamydia pneumoniae syncytial virus bronchiolitis: a randomized, placebo-controlled trial

Early ribavarin treatment of bronchiolitis: effect tions in children and adolescents

Association of Chlamydia pneumoniae 105. Maggon K, Barik S. New drugs and treatment for respiratory syncytial virus. Rev (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset

Association of Chlamydia pneumoniae IgA antiboplacebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for dies with recently symptomatic asthma

Inverse association between Chlamydia biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. pneumoniae respiratory tract infection and initiation of asthma or allergic Structure-activity studies of ketomethylene-containing peptidomimetics

Impact of azithromycin on oropharyngeal antirhinoviral agent, ruprintrivir, in healthy volunteers. Antimicrob Agents carriage of group A Streptococcus and nasopharyngeal carriage of macrolide

Antiviral therapy for enteroviruses and rhinoviruses. Antivir Chem 126. Zuckerman JM. The newer macrolides: azithromycin and clarithromycin

the treatment of community-acquired pneumonia in children

Pharmacologic treatment of bronchi

olitis in infants and children: a systematic review

Curr Opin Pediatr acquired pneumonia in ambulatory children

Role of atypical bacteria and azithromycin 129. Ruuskanen O. Safety and tolerability of azithromycin in pediatric infectious therapy for children with recurrent respiratory tract infections. Pediatr Infect diseases: 2003 update

tract infection aggravates therapy refractory bronchitis or pneumonia in childhood

The use of macrolide antibiotics in patients with cystic fibrosis

Community-acquired pneumonia in children: issues in optimizing

Anti-inflammatory effects of macrolides: an underappreciated bene

Pneumonia due to Chlamydia pneumoniae in children: epidefit in the treatment of community-acquired respiratory tract infections and miology, diagnosis, and treatment

Tick-borne infections in children: epidemiology, clinical mani

festations, and optimal management strategies

Azithromycin reverses airflow obstruction 163-76 in established bronchiolitis obliterans syndrome

Doxycycline for community-acquired pneumonia

Is oral azithromycin effective for the treatment

of cyclosporine-induced gingival hyperplasia in cardiac transplant recipients

cause lower respiratory tract disease in paediatric patients

Fluoroquinolones in paediatrics: a risk

Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: compara

Treatment with erythromycin and, to a lesser, but still consider-